The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Worldwide rates of diagnosis and effective treatment for cystic fibrosis
Open accessAbstract
BACKGROUND: Time has seen management for Cystic Fibrosis (CF) advance drastically, most recently in the development of the disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor. There is currently limited evidence regarding both the global epidemiology of CF and access to this transformative therapy - and therefore where needs are not being met. Therefore, this study aims to define gaps in access to CF treatment. METHODS: Patient data were extracted from established CF registries. Where these were not available, literature searches were conducted alongside an international survey of 51 CF experts to determine the diagnosed patient population. National CF prevalence estimates were combined with registry data on estimated population coverage, to extrapolate the total estimated number of undiagnosed patients. Estimates of ivacaftor/tezacaftor/elexacaftor treatment coverage were extracted from publicly available sales summaries and pricing data. RESULTS: 162,428 [144,606-186,620] people are estimated to be living with CF across 94 countries. Of these, an estimated 105,352 (65%) are diagnosed, with 19,516 (12%) receiving triple combination therapy. We estimated 57,076 patients with undiagnosed CF. Owing to a paucity of high-quality data, estimates of undiagnosed CF in low- and middle-income countries are highly uncertain. Patient registries were available in 45 countries, and used to identify 90% of the estimated diagnosed population. CONCLUSIONS: A significant CF patient burden exists in countries where disease-modifying drugs are unavailable, and final figures are likely underestimates. This analysis shows the potential to improve rates of diagnosis and treatment for CF, so a higher percentage of patients receive the most effective triple combination treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908639 · Cited by 2,198
The future of cystic fibrosis care: a global perspective
Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S., Davies, J. C., Burgel, P.-R., Tullis, E., Castaños, C., Castellani, C., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 974
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Keating, D., Marigowda, G., Burr, L., Daines, C., Mall, M. A., McKone, E. F., Ramsey, B. W., Rowe, S. M., Sass, L. A., Tullis, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807120 · Cited by 726
Shteinberg, M., Haq, I. J., Polineni, D., & Davies, J. C. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32542-3 · Cited by 682
Alsdurf, H., Hill, P. C., Matteelli, A., Getahun, H., & Menzies, D. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30216-x · Cited by 459
The prevalence of cystic fibrosis in the European Union
Farrell, P. M. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.03.007 · Cited by 399
Development of a Cascade of Care for responding to the opioid epidemic.
Williams, A. R., Nunes, E. V., Bisaga, A., Levin, F. R., & Olfson, M. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1546862 · Cited by 332
Veit, G., Roldan, A., Hancock, M. A., Da Fonte, D. F., Xu, H., Hussein, M., Frenkiel, S., Matouk, E., Velkov, T., & Lukacs, G. L. (2020) · JCI Insight · doi:10.1172/jci.insight.139983 · Cited by 250
Newborn Screening for CF across the Globe—Where Is It Worthwhile?
Scotet, V., Gutierrez, H. H., & Farrell, P. M. (2020) · International Journal of Neonatal Screening · doi:10.3390/ijns6010018 · Cited by 145
Morgan, S. G., Vogler, S., & Wagner, A. K. (2017) · Health Policy · doi:10.1016/j.healthpol.2017.02.002 · Cited by 123
Cited by
Bulcaen, M., Kortleven, P., Liu, R. B., Maule, G., Dreano, E., Kelly, M., Ensinck, M. M., Thierie, S., Smits, M., Ciciani, M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101544 · Cited by 69
Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice
Bertolini, A., Nguyen, M., Zehra, S. A., Taleb, S. A., Bauer-Pisani, T., Palm, N., Strazzabosco, M., & Fiorotto, R. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.03.041 · Cited by 13
Metadata
- Authors
- Guo, J., Garratt, A., & Hill, A.
- Venue
- Journal of Cystic Fibrosis
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 21
- Issue
- 3
- Pages
- 456-462
- ISSN
- 1569-1993 (ISSN-L)
- OpenAlex
- W4210526629
- Cited by
- 383
- References
- 16
- FWCI
- 45.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Worldwide rates of diagnosis and effective treatment for cystic fibrosis. https://app.cochat.ai/papers/10.1016/j.jcf.2022.01.009
- The paper
- Guo, J., Garratt, A., & Hill, A. (2022). Worldwide rates of diagnosis and effective treatment for cystic fibrosis. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2022.01.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.